Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Zacks Research to “Strong-Buy” Rating

Zacks Research upgraded shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a hold rating to a strong-buy rating in a research report released on Monday,Zacks.com reports.

Other research analysts have also issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. TD Cowen upgraded Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. Wells Fargo & Company lifted their price target on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Milestone Pharmaceuticals in a research note on Tuesday, January 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Milestone Pharmaceuticals Stock Down 1.2%

NASDAQ MIST traded down $0.03 on Monday, hitting $1.99. 421,750 shares of the company were exchanged, compared to its average volume of 3,037,757. The company has a current ratio of 8.24, a quick ratio of 8.24 and a debt-to-equity ratio of 2.74. The company has a market cap of $169.06 million, a PE ratio of -2.42 and a beta of 0.44. The stock has a fifty day moving average of $2.24 and a 200-day moving average of $1.96. Milestone Pharmaceuticals has a 12 month low of $0.63 and a 12 month high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.05. As a group, analysts forecast that Milestone Pharmaceuticals will post -0.62 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Joseph Oliveto sold 43,000 shares of the business’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $2.25, for a total transaction of $96,750.00. Following the transaction, the chief executive officer directly owned 303,721 shares in the company, valued at approximately $683,372.25. The trade was a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 19.50% of the company’s stock.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several hedge funds have recently modified their holdings of MIST. Sapient Capital LLC bought a new position in shares of Milestone Pharmaceuticals in the third quarter valued at approximately $25,000. Bank of America Corp DE grew its stake in Milestone Pharmaceuticals by 200,550.0% in the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after purchasing an additional 16,044 shares during the period. Stephenson & Company Inc. bought a new position in Milestone Pharmaceuticals in the 3rd quarter valued at $40,000. Creative Planning increased its position in shares of Milestone Pharmaceuticals by 74.6% during the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Bay Rivers Group raised its stake in shares of Milestone Pharmaceuticals by 72.9% during the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after purchasing an additional 12,170 shares during the period. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.